<DOC>
	<DOCNO>NCT02812771</DOCNO>
	<brief_summary>Safety PK daily topical application efinaconazole treatment pediatric subject mild severe onychomycosis toenail .</brief_summary>
	<brief_title>Safety Pharmacokinetics Efinaconazole Topical Solution Subjects With Mild Severe Onychomycosis</brief_title>
	<detailed_description>This open label , single-arm study design evaluate safety PK daily topical application efinaconazole treatment pediatric subject mild severe onychomycosis toenail .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Efinaconazole</mesh_term>
	<criteria>Key Male female subject race , 6 16 year age ( inclusive ) . PK Subset : Male female subject race , 12 16 year age ( inclusive ) . Verbal write informed consent/assent obtain subject and/or parent legal guardian . Good general health , assess investigator , base subject 's medical history , physical examination , safety laboratory test . Target great toenail subject , great toenails subject PK subset , must evidence toenail growth , per subject 's report monthly clip need . Subjects parents/legal guardian willing comply study instruction return investigational center require visit ( visit schedule length visit provide ensure subject meet requirement adequate transportation ) . Key Females pregnant , nurse infant , plan pregnancy study period . History immunosuppression and/or clinical sign indicative possible immunosuppression , determine investigator , know human immunodeficiency virus infection . History diabetes uncontrolled determine investigator ( diabetes control diet medication exclude subject ) . Presence toenail infection addition dermatophytes , Scytalidium determine investigator ( candidal onychomycosis infection , concurrent positive dermatophyte culture , acceptable ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>